Edwards Lifesciences Co. (NYSE:EW) Position Decreased by Allworth Financial LP

Allworth Financial LP reduced its holdings in Edwards Lifesciences Co. (NYSE:EW) by 26.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,337 shares of the medical research company’s stock after selling 1,218 shares during the quarter. Allworth Financial LP’s holdings in Edwards Lifesciences were worth $220,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Edwards Lifesciences by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 52,964,394 shares of the medical research company’s stock valued at $5,061,277,000 after acquiring an additional 600,994 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Edwards Lifesciences by 4.3% during the second quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock valued at $1,827,347,000 after purchasing an additional 809,605 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Edwards Lifesciences by 57.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock valued at $622,695,000 after purchasing an additional 2,390,137 shares during the last quarter. Champlain Investment Partners LLC boosted its position in shares of Edwards Lifesciences by 3.1% in the 1st quarter. Champlain Investment Partners LLC now owns 2,964,168 shares of the medical research company’s stock valued at $283,256,000 after purchasing an additional 88,205 shares during the period. Finally, AustralianSuper Pty Ltd increased its stake in Edwards Lifesciences by 14.2% in the 2nd quarter. AustralianSuper Pty Ltd now owns 2,778,812 shares of the medical research company’s stock worth $256,679,000 after purchasing an additional 344,465 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In other news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the sale, the vice president now directly owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total transaction of $347,550.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,262,521.36. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares in the company, valued at $2,051,843.35. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 16,250 shares of company stock worth $1,099,238. 1.29% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Wells Fargo & Company reduced their price objective on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 25th. Barclays cut their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research report on Monday. Finally, The Goldman Sachs Group dropped their price target on Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Sixteen analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $75.67.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $68.63 on Thursday. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87. The stock has a market capitalization of $41.36 billion, a P/E ratio of 29.58, a P/E/G ratio of 3.00 and a beta of 1.13. The business has a 50-day moving average of $68.07 and a two-hundred day moving average of $77.92. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The firm had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter in the prior year, the business earned $0.59 earnings per share. The company’s revenue was up 8.9% on a year-over-year basis. On average, equities research analysts predict that Edwards Lifesciences Co. will post 2.61 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.